US Patent 10,647,698: What Claims 1–6 Cover, Claim Scope Boundaries, and the US Patent Landscape
US Patent 10,647,698 is a US-listed patent with broad compound coverage at the structural level and a secondary composition-of-matter claim. Based on the claim text provided, the patent’s US scope centers on “a compound having the structure” recited in Claims 1–5, with generic cover for pharmaceutically acceptable salts, stereochemical variants, isotopic derivatives, and prodrugs (Claim 1), plus more limited stereochemical/salt coverage in Claims 2–5. Claim 6 adds formulation coverage for a pharmaceutical composition that includes one of the claimed compounds plus a pharmaceutically acceptable carrier.
Because the actual structural formulas embedded in Claims 1–5 are not reproduced in the prompt, the landscape below is constrained to a structural-claims-first analysis of what the claim language does and does not cover, and how that typically interacts with typical US second-generation IP bundles (synthesis, intermediates, crystal forms, formulation/process, and method-of-use patents). No litigation or Orange Book listing status can be asserted from the provided information alone.
What does US Patent 10,647,698 claim in plain English (Claims 1–6)?
Short answer: It claims specific chemical entities defined by structure (Claims 1–5) and a corresponding pharmaceutical composition that contains such an entity (Claim 6). Claim 1 is the widest because it expressly includes salts, enantiomers, stereoisomers, isotopic derivatives, and prodrugs. Claims 2–5 focus on narrower subsets of stereochemistry and salts depending on which variant class is expressly permitted.
Claim 1 scope: “structure” plus full derivative family
Featured snippet answer: Claim 1 is a structural compound claim with broad derivative coverage, including salts, enantiomers, stereoisomers, isotopic derivatives, and prodrugs.
Claim 1 requires:
- A “compound having the structure” (formula not shown in the prompt), and
- A covered variant category, expressly including:
- pharmaceutically acceptable salts
- enantiomers
- stereoisomers
- isotopic derivatives
- prodrugs of any of the foregoing
Implication for design-arounds: If the marketed candidate is within the structural “core” of the claim, the derivative carve-outs are unlikely to help. Claim 1’s express inclusion of isotopic derivatives and prodrugs closes common “label-to-avoid” routes that rely on switching isotopes or introducing promoieties, as long as the “compound having the structure” requirement is still met.
Claims 2–5 scope: narrower derivative subsets
Featured snippet answer: Claims 2–5 also cover structure-defined compounds, but only for salts and selected stereochemical variants (the prompt indicates enantiomer and/or stereoisomer combinations).
From the provided text:
- Claim 2: structure + pharmaceutically acceptable salt, enantiomer, or stereoisomer
- Claim 3: structure + pharmaceutically acceptable salt, enantiomer, or stereoisomer
- Claim 4: structure + pharmaceutically acceptable salt, enantiomer, or stereoisomer
- Claim 5: structure + pharmaceutically acceptable salt, enantiomer, or stereoisomer
Because the prompt repeats the same derivative pattern for Claims 2–5, the principal distinction among Claims 2–5 is likely which structural formula is recited (different substituents, ring variations, or alternative tautomers) even if the derivative categories are similar. In practice, those multiple claims typically map to a set of related compounds (for example, positional isomers, homologs, or alternative substituent embodiments) that share the same derivative rules.
Claim 6 scope: composition-of-matter for administration with a carrier
Featured snippet answer: Claim 6 covers a pharmaceutical composition comprising the claimed compound plus a pharmaceutically acceptable carrier.
Claim 6 requires:
- a pharmaceutical composition
- comprising a compound of Claim 1 (not explicitly Claims 2–5 as written), plus
- a pharmaceutically acceptable carrier
Implication for generics and lifecycle: Composition claims can be strong against generic products even when the active ingredient is similar, unless there is a successful non-infringement or invalidity pathway on the composition claim itself, or unless the generic uses a materially different formulation that avoids infringement (which is difficult if the claim is carrier-generic).
How broad is “pharmaceutically acceptable salt, enantiomer, stereoisomer, isotopic derivative, and prodrug” in US claim construction?
Short answer: Those terms materially expand claim reach beyond a single neutral parent compound, creating infringement exposure across multiple commercial variants that share the same claimed structural core.
Salts
“Pharmaceutically acceptable salts” typically reaches salts formed from common inorganic and organic acids/bases. If the structural claim is satisfied for the salt form, infringement is typically straightforward.
Design-around risk: Switching salt form rarely eliminates infringement when the patent includes “pharmaceutically acceptable salt” by class.
Enantiomers and stereoisomers
Enantiomer and stereoisomer language generally sweeps both single stereoisomer and mixtures, provided they remain within the structurally defined scaffold.
Practical outcome: If an NDA or ANDA uses one enantiomer, it can still infringe if that enantiomer is within the structural claim.
Isotopic derivatives
Isotopic derivatives cover isotope-labeled variants (for example, ^2H, ^13C, ^14C, etc.), which can matter for imaging or internal standards. Inclusion in Claim 1 can create unexpectedly broad scope.
Design-around risk: Labs sometimes attempt to license a labeled variant under separate IP. If the structural core matches, Claim 1 still covers.
Prodrugs
Prodrug inclusion can catch esterifications, amide promoieties, and other bioconversion masks, when the prodrug falls within the “compound having the structure” requirement as claimed.
High-level note: Infringement still turns on whether the prodrug’s chemical structure falls within the structural claim formula. The phrase “prodrugs of any of the foregoing” is typically read to cover prodrug derivatives of the covered parent/variants.
What is the effective “claim boundary” of US Patent 10,647,698 if the formula is the limiting element?
Short answer: The structural formula is the limiting element. If a competitor’s API is outside the recited scaffold, derivative categories do not save infringement.
Even with broad derivative categories, US structural claims usually require that the accused compound literally contains the claimed structural features. In other words:
- Derivative language broadens what counts as “the same compound family.”
- It does not expand the scaffold beyond what the structure recites.
What the prompt’s missing structures mean for scope
The prompt omits the actual formula images/text after “having the structure:”. Without the exact structural definitions, the analysis can’t enumerate:
- which functional groups are included/excluded
- what ring systems are covered
- what substituent patterns are permitted
So the only defensible statement is that Claims 1–5 are scaffold-limited, while Claims 1’s derivative classes are expansive.
How does Claim 6 interact with common generic formulation strategies?
Short answer: Claim 6 is carrier-generic, making it harder to design around by switching excipients.
Because Claim 6 broadly covers “a pharmaceutical composition comprising” the claimed compound and a pharmaceutically acceptable carrier, generic strategies typically rely on one of these outcomes:
- non-infringement (API does not fall within Claim 1 structural definition)
- invalidity (e.g., anticipation/obviousness of the structural entities or composition)
- carve-out via a non-infringing formulation is less likely when the only formulation limitation is “carrier” and the claim is otherwise open-ended
Most likely pressure points for a challenger:
- the validity of the compound scaffold claims (Claims 1–5), since composition claims tend to follow
- any dependent limitations that might exist in full claims text (not provided)
What other patent types typically surround a broad compound patent like US 10,647,698?
Short answer: A broad structure claim is often paired with additional US IP in the same family that can cover manufacturing, specific stereochemical selections, polymorph/crystal forms, and method-of-use. Without family documents, this is a standard landscape mapping rather than an identified enumeration.
Common companion US patent categories
- Process patents (synthesis routes, intermediates)
- key for manufacturing licenses, especially for ANDA and complex molecules
- Intermediate and intermediate-use patents
- cover chemical intermediates that might be generated during manufacturing even if the final API is the same
- Solid-state patents
- polymorphs, hydrates, solvates, amorphous forms, particle size
- Formulation patents beyond simple “carrier”
- specific release profiles, excipient systems, particle engineering, taste masking
- Method-of-use or dosing regimens
- if the molecule is used for a specific indication, method claims can dominate Paragraph IV leverage
- Biosimilar-style equivalents (only if biologic)
- not inferable from prompt; US 10,647,698 appears to be small-molecule chemical claims
What does the claims structure imply about Paragraph IV ANDA/505(b)(2) risk?
Short answer: If an ANDA’s active ingredient is within the claimed structural scaffold, the presence of a composition claim increases risk of infringement exposure beyond the API itself.
Typical risk logic for US generics
- ANDA ANDA-API infringement is usually analyzed against compound claims first.
- Composition claims can extend exposure to finished dosage forms.
- If Claim 6 is broad enough to cover standard dosage forms (tablets/capsules/liquids) using pharmaceutically acceptable carriers, infringement arguments can be straightforward.
Litigant leverage
- Generic challengers commonly attack broad compound claims on novelty/obviousness.
- Brand owners often preserve injunction leverage if validity is strong and the generic uses the claimed API.
Without the actual structural recitals and without knowing which drug product is associated with the patent, the litigation timing and viability cannot be asserted.
How strong is the patent estate for US 10,647,698 likely to be based on claim breadth?
Short answer: Breadth cuts both ways. Broad derivative language increases infringement coverage; it can also create validity exposure if prior art discloses the scaffold plus routine stereochemical variations.
Strength signals embedded in the claim language
- The structure-based compound claims are classic “core” claims for small molecules.
- Claim 1’s explicit derivative family language suggests the applicant sought comprehensive coverage around the parent scaffold.
Validity risk signals embedded in broad coverage
- If prior art describes the same scaffold and common stereochemical variants, anticipation can apply.
- If prior art describes closely related scaffolds and routine modifications, obviousness can be argued broadly.
This is a legal inference grounded in typical US patent practice; it is not a determination of validity for this specific patent family.
Timeline and exclusivity questions: When does US 10,647,698 lose exclusivity?
Short answer: Cannot be computed from the provided information because patent expiration depends on:
- the filing date (utility patent term from earliest effective non-provisional filing, subject to adjustments)
- any PTA/PTE
- whether terminal disclaimer is present
No filing date, grant date, or PTA/PTE values are provided in the prompt. Therefore, a precise expiration timeline cannot be produced.
Which companies are challenging or have entered with generics or biosimilars against US 10,647,698?
Short answer: Not determinable from the provided claim text.
To identify challengers, you need Orange Book patent-to-product mappings, FDA approvals, and filed Paragraph IV certifications. None of those data are included in the prompt.
What formulations are protected by US 10,647,698?
Short answer: At minimum, any pharmaceutical composition that includes the claimed compound (Claim 1 compound) plus a pharmaceutically acceptable carrier.
Covered dosage forms (likely, based on claim breadth)
- tablets
- capsules
- oral solutions/suspensions
- parenteral preparations
- topical preparations
Those are not explicitly recited. The claim language does not limit route or dosage form. Under typical claim interpretation, “pharmaceutically acceptable carrier” is broad enough to encompass most standard pharmaceutical forms.
Key Takeaways
- US Patent 10,647,698 claims structure-defined compounds (Claims 1–5) with Claim 1 providing the broadest derivative coverage: salts, enantiomers, stereoisomers, isotopic derivatives, and prodrugs.
- Claim 6 provides composition coverage for a pharmaceutical composition containing a Claim 1 compound plus a pharmaceutically acceptable carrier, making formulation design-around less effective if the active ingredient falls within the claimed scaffold.
- The decisive infringement boundary is the recited structural formula(s). Derivative language expands “what counts,” but does not expand the scaffold beyond what the structure recites.
- Patent term/exclusivity, Orange Book status, Paragraph IV landscape, and specific competitors cannot be determined from the claim text alone.
FAQs
1) Does Claim 1 cover both the neutral parent compound and its prodrugs?
Yes. Claim 1 expressly includes prodrugs “of any of the foregoing” variants, provided the prodrug structure still satisfies the structural “compound having the structure” requirement.
2) Can a generic avoid infringement by using a different salt form?
Not if the alternative salt is still “pharmaceutically acceptable” and still within the claimed structural scope, since Claim 1 includes pharmaceutically acceptable salts.
3) Does Claim 6 protect the finished dosage form even if the carrier/excipients change?
Claim 6 is carrier-generic. If the dosage form contains the claimed compound and uses a pharmaceutically acceptable carrier, changing excipients typically does not remove infringement risk.
4) Are isotopically labeled compounds covered by this patent?
Yes, for the claimed scaffold, because Claim 1 includes isotopic derivatives.
5) Is a different stereoisomer protected by Claims 1–5?
Yes. The claims include enantiomers and stereoisomers within the structure-defined scaffold, so different stereochemical selections can still fall within scope.
References
- United States Patent 10,647,698 (claims 1–6), provided in the prompt.
